Philip Morris Doubles Colorado ZYN Investment to $1.2 Billion as U.S. Nicotine Pouch Demand Grows

Philip Morris International ($PM) said it has doubled its planned investment in its Aurora, Colorado manufacturing campus to approximately $1.2 billion through 2028, expanding production of ZYN nicotine pouches. The company's first U.S. greenfield manufacturing campus began commercial production this month and will serve domestic demand while supporting exports to Asia, Latin America and the Caribbean.

• The Aurora campus represents a planned $1.2 billion investment from 2024 through 2028, up from the original $600 million announced in 2024.
• The 780,000-square-foot facility is expected to employ about 500 people, support 1,000 indirect jobs and generate roughly $550 million in annual economic impact.
• PMI said the campus strengthens its U.S. manufacturing network alongside facilities in Kentucky and North Carolina.
• The expansion follows the FDA's authorization of 20 ZYN products as modified-risk tobacco products, allowing reduced-risk marketing compared with cigarettes.

Relevant Companies

• Philip Morris International ($PM) – The investment expands ZYN production capacity and supports the company's smoke-free growth strategy.
• British American Tobacco ($BTI) – Competes in the modern oral nicotine market and could face increased competition as PMI expands production.
• Altria ($MO) – A major U.S. nicotine products company competing in the growing smoke-free and oral nicotine category.

Editor’s Note: This is a developing story. This article may be updated as more details become available.